The potential applications of T cell receptor (TCR)-like antibody in cervical cancer immunotherapy

Dass, Sylvia Annabel; Rajan, Rehasri Selva; Tye, Gee Jun; Balakrishnan, Venugopal

doi:10.1080/21645515.2021.1913960

Cited by 5 publications

(5 citation statements)

References 117 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Distinguishing from conventional mAbs, TCR‐like antibodies or TCR‐mimic antibodies recognize antigen peptides presented on a major histocompatibility complex (MHC) molecule 116 . Three TCR‐like mAbs were developed based on HLA‐A*0201 presented peptides LMP1 125‐133 (L1), LMP2A 426‐434 (L2), and EBNA1 562‐670 (E1) 109,110 .…”

Section: Ebv Antibodies As Antiviral Agents For Infection and Its Ass...mentioning

confidence: 99%

“…Fabs targeting LMP1 and LMP2A have the potential to offer innovative therapeutic options for patients with LMP1-positive and LMP2A-positive tumors. However, further robust evidence and optimized combinations of treatment modalities are still warranted.Distinguishing from conventional mAbs, TCR-like antibodies or TCR-mimic antibodies recognize antigen peptides presented on a major histocompatibility complex (MHC) molecule 116. Three TCR-like mAbs were developed based on HLA-A*0201 presented peptides LMP1 125-133 (L1), LMP2A 426-434 (L2), and EBNA1 562-670 (E1) 109,110.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Anti‐EBV antibodies: Roles in diagnosis, pathogenesis, and antiviral therapy

Xie

Zhong

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

Epstein-Barr virus (EBV) infection is prevalent in global population and associated with multiple malignancies and autoimmune diseases. During the infection, EBV-harbored or infected cell-expressing antigen could elicit a variety of antibodies with significant role in viral host response and pathogenesis. These antibodies have been extensively evaluated and found to be valuable in predicting disease diagnosis and prognosis, exploring disease mechanisms, and developing antiviral agents. In this review, we discuss the versatile roles of EBV antibodies as important biomarkers for EBV-related diseases, potential driving factors of autoimmunity, and promising therapeutic agents for viral infection and pathogenesis.

show abstract

Section: Ebv Antibodies As Antiviral Agents For Infection and Its Ass...mentioning

confidence: 99%

mentioning

confidence: 99%

Anti‐EBV antibodies: Roles in diagnosis, pathogenesis, and antiviral therapy

Xie

Zhong

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…In addition to the mentioned immunotherapies for cervical cancer, further promising immunotherapy strategies such as the engineered T cell receptor (TCR)-like antibody therapy and engineered chimeric antigen receptor (CAR) T cell therapy have yielded promising outcomes in terms of cytotoxicity and cervical tumor regression. Resistance to T-cell-mediated recognition, toxicity, patient specificity (genetically engineered T cells, no standard treatment) and high costs are current hurdles that still need to be overcome [ 60 , 61 ].…”

Section: Medical Therapymentioning

confidence: 99%

Challenges in the Diagnosis and Individualized Treatment of Cervical Cancer

et al. 2023

View full text Add to dashboard Cite

Cervical cancer is still the fourth most common cancer in women throughout the world; an estimated 604,000 new cases were observed in 2020. Better knowledge of its pathogenesis, gained in recent years, has introduced new preventive and diagnostic approaches. Knowledge of its pathogenesis has made it possible to provide individualized surgical and drug treatment. In industrialized countries, cervical cancer has become a less frequent tumor entity due to the accessibility of the human papilloma virus vaccination, systematic preventive programs/early detection programs, health care infrastructure and the availability of effective therapy options. Nevertheless, globally, neither mortality nor morbidity has been significantly reduced over the past 10 years, and therapy approaches differ widely. The aim of this review is to address recent advances in the prevention, diagnostic investigation and treatment of cervical cancer globally, focusing on advances in Germany, with a view toward providing an updated overview for clinicians. The following aspects are addressed in detail: (a) the prevalence and causes of cervical cancer, (b) diagnostic tools using imaging techniques, cytology and pathology, (c) pathomechanisms and clinical symptoms of cervical cancer and (d) different treatment approaches (pharmacological, surgical and others) and their impact on outcomes.

show abstract

“…In the aspect of tuberculosis, the TCR-like antibody-based immunotoxins would contribute to the elimination of TB-infected cells without affecting the normal cells (178). Other modifications include antibody fusion molecules and combinational therapy which will improve the overall treatment efficiency of many diseases including TB, infection, cancer, infectious diseases and many more (179). So far, there are several successful preliminary reports on the generation of TCR-like antibodies against Mtb using a human single domain antibody phage display library (180)(181)(182).…”

Section: T Cell Receptor (Tcr)-like/mimic Antibodymentioning

confidence: 99%

“…One way to overcome this limitation is to carefully select the HLAs based on the predominant distribution of HLA globally. HLA-A2 is known to be found in the majority of the world population while HLA-A11 and HLA-A24 are common in the Asian population ( 179 ). Previously, all three HLAs were selected in a TCR-like antibody study to ensure the findings were applicable for a wide range of population ( 180 , 181 ).…”

Section: T Cell Receptor (Tcr)-like/mimic Antibodymentioning

confidence: 99%

The COVID-19/Tuberculosis Syndemic and Potential Antibody Therapy for TB Based on the Lessons Learnt From the Pandemic

et al. 2022

Self Cite

View full text Add to dashboard Cite

2020 will be marked in history for the dreadful implications of the COVID-19 pandemic that shook the world globally. The pandemic has reshaped the normality of life and affected mankind in the aspects of mental and physical health, financial, economy, growth, and development. The focus shift to COVID-19 has indirectly impacted an existing air-borne disease, Tuberculosis. In addition to the decrease in TB diagnosis, the emergence of the TB/COVID-19 syndemic and its serious implications (possible reactivation of latent TB post-COVID-19, aggravation of an existing active TB condition, or escalation of the severity of a COVID-19 during TB-COVID-19 coinfection), serve as primary reasons to equally prioritize TB. On a different note, the valuable lessons learnt for the COVID-19 pandemic provide useful knowledge for enhancing TB diagnostics and therapeutics. In this review, the crucial need to focus on TB amid the COVID-19 pandemic has been discussed. Besides, a general comparison between COVID-19 and TB in the aspects of pathogenesis, diagnostics, symptoms, and treatment options with importance given to antibody therapy were presented. Lastly, the lessons learnt from the COVID-19 pandemic and how it is applicable to enhance the antibody-based immunotherapy for TB have been presented.

show abstract

The potential applications of T cell receptor (TCR)-like antibody in cervical cancer immunotherapy

Cited by 5 publications

References 117 publications

Anti‐EBV antibodies: Roles in diagnosis, pathogenesis, and antiviral therapy

Anti‐EBV antibodies: Roles in diagnosis, pathogenesis, and antiviral therapy

Challenges in the Diagnosis and Individualized Treatment of Cervical Cancer

The COVID-19/Tuberculosis Syndemic and Potential Antibody Therapy for TB Based on the Lessons Learnt From the Pandemic

Contact Info

Product

Resources

About